Soleno Therapeutics (SLNO) Competitors $75.05 -0.53 (-0.70%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SLNO vs. SOLV, SNN, PEN, STVN, GKOS, NARI, INSP, IRTC, BLCO, and TMDXShould you be buying Soleno Therapeutics stock or one of its competitors? The main competitors of Soleno Therapeutics include Solventum (SOLV), Smith & Nephew (SNN), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Inari Medical (NARI), Inspire Medical Systems (INSP), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), and TransMedics Group (TMDX). These companies are all part of the "medical equipment" industry. Soleno Therapeutics vs. Solventum Smith & Nephew Penumbra Stevanato Group Glaukos Inari Medical Inspire Medical Systems iRhythm Technologies Bausch + Lomb TransMedics Group Soleno Therapeutics (NASDAQ:SLNO) and Solventum (NYSE:SOLV) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk, media sentiment and community ranking. Do insiders and institutionals hold more shares of SLNO or SOLV? 97.4% of Soleno Therapeutics shares are held by institutional investors. 12.3% of Soleno Therapeutics shares are held by company insiders. Comparatively, 0.1% of Solventum shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer SLNO or SOLV? In the previous week, Solventum had 12 more articles in the media than Soleno Therapeutics. MarketBeat recorded 20 mentions for Solventum and 8 mentions for Soleno Therapeutics. Solventum's average media sentiment score of 1.40 beat Soleno Therapeutics' score of 1.18 indicating that Solventum is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Soleno Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solventum 15 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, SLNO or SOLV? Solventum has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoleno TherapeuticsN/AN/A-$38.99M-$4.62-16.24Solventum$8.31B1.55$373.71M$2.1634.57 Is SLNO or SOLV more profitable? Solventum's return on equity of 0.00% beat Soleno Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Soleno TherapeuticsN/A -61.99% -55.21% Solventum N/A N/A N/A Do analysts prefer SLNO or SOLV? Soleno Therapeutics currently has a consensus target price of $106.78, suggesting a potential upside of 42.28%. Solventum has a consensus target price of $80.29, suggesting a potential upside of 7.52%. Given Soleno Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Soleno Therapeutics is more favorable than Solventum.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Solventum 1 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.10 Does the MarketBeat Community prefer SLNO or SOLV? Soleno Therapeutics received 321 more outperform votes than Solventum when rated by MarketBeat users. Likewise, 72.75% of users gave Soleno Therapeutics an outperform vote while only 7.41% of users gave Solventum an outperform vote. CompanyUnderperformOutperformSoleno TherapeuticsOutperform Votes32372.75% Underperform Votes12127.25% SolventumOutperform Votes27.41%Underperform Votes2592.59% SummarySoleno Therapeutics and Solventum tied by winning 8 of the 16 factors compared between the two stocks. Get Soleno Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLNO vs. The Competition Export to ExcelMetricSoleno TherapeuticsElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.78B$3.34B$5.43B$8.48BDividend YieldN/A1.73%5.22%4.11%P/E Ratio-22.6117.5026.7920.05Price / SalesN/A82.07394.72116.44Price / CashN/A44.0938.2534.62Price / Book14.543.866.864.61Net Income-$38.99M$94.03M$3.22B$248.19M7 Day Performance2.16%6.65%6.83%2.97%1 Month Performance8.88%30.40%13.73%16.58%1 Year Performance69.53%-9.55%18.22%8.16% Soleno Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLNOSoleno Therapeutics4.8655 of 5 stars$75.05-0.7%$106.78+42.3%+59.6%$3.78BN/A-22.6130News CoveragePositive NewsSOLVSolventum1.2884 of 5 stars$74.85+6.6%$79.00+5.5%+20.4%$12.95B$8.25B27.2222,000Positive NewsAnalyst UpgradeSNNSmith & Nephew2.266 of 5 stars$28.43+0.3%$28.00-1.5%+12.9%$12.45B$5.81B13.1620,100News CoveragePENPenumbra4.4338 of 5 stars$296.98-0.1%$302.40+1.8%+39.5%$11.50B$1.24B873.473,900Positive NewsSTVNStevanato Group1.2604 of 5 stars€23.64-1.5%N/A+21.2%$7.16B$1.10B50.304,650Positive NewsGKOSGlaukos4.6737 of 5 stars$94.57+5.1%$134.67+42.4%-10.7%$5.40B$404.52M-32.95780Positive NewsNARIInari Medical0.472 of 5 stars$79.97flat$69.22-13.4%N/A$4.68B$493.63M-59.24800News CoverageINSPInspire Medical Systems4.7118 of 5 stars$156.54+3.5%$211.91+35.4%-3.4%$4.62B$840.11M90.49760Positive NewsGap DownIRTCiRhythm Technologies1.3027 of 5 stars$137.80+0.1%$128.55-6.7%+52.5%$4.40B$618.59M-37.861,790Positive NewsBLCOBausch + Lomb4.3015 of 5 stars$11.91+5.6%$15.50+30.2%-19.2%$4.21B$4.83B-13.0812,500Gap UpTMDXTransMedics Group1.4365 of 5 stars$118.73+6.5%$126.70+6.7%-10.0%$4.02B$488.23M126.31210Positive News Related Companies and Tools Related Companies Solventum Alternatives Smith & Nephew Alternatives Penumbra Alternatives Stevanato Group Alternatives Glaukos Alternatives Inari Medical Alternatives Inspire Medical Systems Alternatives iRhythm Technologies Alternatives Bausch + Lomb Alternatives TransMedics Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLNO) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
